Exosome Pioneer Evox's Series B Gives It Needed Financial Runway, CEO Says
Privately held Evox Therapeutics raised £35.5m ($45.4m) of new capital in a series B financing round, adding to the £10m injected by a series A seed financing a year ago.
You may also be interested in...
Sanofi is to acquire Belgian nanobody developer Ablynx in an all-cash deal worth €3.9bn, 50% higher than the spurned bid by Novo Nordisk.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.